Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.
3.

Mortality and associated risk factors in consecutive patients admitted to a UK NHS trust with community acquired bacteraemia.

Hounsom L, Grayson K, Melzer M.

Postgrad Med J. 2011 Nov;87(1033):757-62. doi: 10.1136/pgmj.2010.116616. Epub 2011 Jul 28.

PMID:
21798969
4.

Clinical impact of extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with biliary tract infection.

Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.

Dig Dis Sci. 2013 Mar;58(3):841-9. doi: 10.1007/s10620-012-2398-7. Epub 2012 Sep 14.

PMID:
22975797
5.

Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia.

Lye DC, Wijaya L, Chan J, Teng CP, Leo YS.

Ann Acad Med Singapore. 2008 Oct;37(10):831-4.

6.

Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge.

Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP, Moreno-Ramos F, Rico-Nieto A, Ruiz-Carrascoso G, Gómez-Gil R, Arribas-López JR, Mingorance J, Paño-Pardo JR.

Clin Microbiol Infect. 2013 Feb;19(2):E72-9. doi: 10.1111/1469-0691.12091. Epub 2012 Dec 12.

7.

Gram-negative bacteraemia in non-ICU patients: factors associated with inadequate antibiotic therapy and impact on outcomes.

Marschall J, Agniel D, Fraser VJ, Doherty J, Warren DK.

J Antimicrob Chemother. 2008 Jun;61(6):1376-83. doi: 10.1093/jac/dkn104. Epub 2008 Mar 15.

8.
9.

Propensity score-matched analysis comparing the therapeutic efficacies of cefazolin and extended-spectrum cephalosporins as appropriate empirical therapy in adults with community-onset Escherichia coli, Klebsiella spp. and Proteus mirabilis bacteraemia.

Hsieh CC, Lee CH, Hong MY, Hung YP, Lee NY, Ko WC, Lee CC.

Int J Antimicrob Agents. 2016 Dec;48(6):712-718. doi: 10.1016/j.ijantimicag.2016.09.015. Epub 2016 Oct 26.

PMID:
27836382
10.

Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitals.

Fitzpatrick JM, Biswas JS, Edgeworth JD, Islam J, Jenkins N, Judge R, Lavery AJ, Melzer M, Morris-Jones S, Nsutebu EF, Peters J, Pillay DG, Pink F, Price JR, Scarborough M, Thwaites GE, Tilley R, Walker AS, Llewelyn MJ; United Kingdom Clinical Infection Research Group.

Clin Microbiol Infect. 2016 Mar;22(3):244-51. doi: 10.1016/j.cmi.2015.10.034. Epub 2015 Nov 11.

11.

Cefotaxime resistance and outcome of Klebsiella spp bloodstream infection.

Ortega M, Marco F, Soriano A, Almela M, Martínez JA, López J, Pitart C, Mensa J.

Eur J Clin Microbiol Infect Dis. 2011 Dec;30(12):1599-605. doi: 10.1007/s10096-011-1266-2. Epub 2011 Apr 21.

PMID:
21509474
12.

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.

Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC.

Antimicrob Agents Chemother. 2002 May;46(5):1481-91.

13.

Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.

Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, Yoo JH, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS.

Ann Hematol. 2013 Apr;92(4):533-41. doi: 10.1007/s00277-012-1631-y. Epub 2012 Nov 17.

PMID:
23161391
14.

[Microbiologic study of the bile culture and antimicrobial susceptibility in patients with biliary tract infection].

Bae WK, Moon YS, Kim JH, Lee SH, Kim NH, Kim KA, Lee JS, Um TH, Cho CR.

Korean J Gastroenterol. 2008 Apr;51(4):248-54. Korean.

15.

Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study.

Peralta G, Lamelo M, Alvarez-García P, Velasco M, Delgado A, Horcajada JP, Montero M, Roiz MP, Fariñas MC, Alonso J, Martínez LM, Gutiérrez-Macías A, Alava JA, Rodríguez A, Fleites A, Navarro V, Sirvent E, Capdevila JA; SEMI- BLEE STUDY GROUP.

BMC Infect Dis. 2012 Oct 5;12:245. doi: 10.1186/1471-2334-12-245.

16.

Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study.

Thom KA, Schweizer ML, Osih RB, McGregor JC, Furuno JP, Perencevich EN, Harris AD.

BMC Infect Dis. 2008 Sep 15;8:116. doi: 10.1186/1471-2334-8-116.

17.

[Bacteremia caused by Escherichia coli and Klebsiella pneumoniae producing extended-spectrum betalactamases: mortality and readmission-related factors].

Perianes-Díaz ME, Novo-Veleiro I, Solís-Díaz K, Prolo-Acosta A, García-García I, Alonso-Claudio G.

Med Clin (Barc). 2014 May 6;142(9):381-6. doi: 10.1016/j.medcli.2013.01.048. Epub 2013 Jun 2. Spanish.

PMID:
23735867
18.

Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.

Martínez JA, Aguilar J, Almela M, Marco F, Soriano A, López F, Balasso V, Pozo L, Mensa J.

J Antimicrob Chemother. 2006 Nov;58(5):1082-5. Epub 2006 Sep 1.

PMID:
16950822
19.

Clinical and microbiologic characteristics of adult patients with recurrent bacteraemia caused by extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.

Lee CH, Su LH, Chen FJ, Tang YF, Chien CC, Liu JW.

Clin Microbiol Infect. 2015 Dec;21(12):1105.e1-8. doi: 10.1016/j.cmi.2015.07.025. Epub 2015 Aug 10.

20.

Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center.

Marín M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratalà J.

Medicine (Baltimore). 2014 May;93(3):143-9. doi: 10.1097/MD.0000000000000026.

Supplemental Content

Support Center